|
Source – European Medicines Agency (EMEA) - The European Medicines Agency (EMEA) has recommended to extend the indication for Prozac (fluoxetine) and associated names to include the treatment of children of 8 years of age and over who suffer from moderate to severe depression and who do not respond to psychological therapy.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benfits of using Prozac for this indication
outweigh its potential risks. The Committee has asked the authorisation holder Eli Lilly, to carry out additional studies to ensure that the safety profile of Prozac remains acceptable.
For more information go to: http://www.emea.eu.int/pdfs/human/press/pr/20255406en.pdf
Prepared by Susan Wileman Medicines Information Technician
Date of Preparation: 7th June 2006
|
